Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.54 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1404944 | 1.00 | MAPT (0.63) | MAPTALDH1A1KDM4EL3MBTL1GAA | |
| SCHEMBL30377588 | 1.00 | MAPT (0.63) | MAPTALDH1A1KDM4EL3MBTL1GAA | |
| SCHEMBL31356854 | 1.00 | MAPT (0.63) | MAPTALDH1A1KDM4EL3MBTL1GAA | |
| SCHEMBL7687333 | 0.85 | MAPT (0.46) | MAPTALDH1A1KDM4EL3MBTL1GAA | |
| SCHEMBL7687335 | 0.85 | MAPT (0.46) | MAPTALDH1A1KDM4EL3MBTL1GAA | |
| SCHEMBL14926715 | 0.84 | GABRA1 (0.50) | MAPTALDH1A1KDM4EL3MBTL1GAA | |
| SCHEMBL29419102 | 0.83 | MAPT (0.65) | MAPTALDH1A1KDM4EL3MBTL1GAA | |
| SCHEMBL481451 | 0.83 | MAPT (0.65) | MAPTALDH1A1KDM4EL3MBTL1GAA | |
| SCHEMBL1193408 | 0.83 | MAPT (0.65) | MAPTALDH1A1KDM4EL3MBTL1GAA | |
| SCHEMBL165227 | 0.83 | MAPT (0.65) | MAPTALDH1A1KDM4EL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113620901-B | Crown ether derived chiral 1,1 '-bi-2, 2' -naphthol, preparation method and application thereof | 杭州师范大学 | 2023-02-10 | — | — | CN | claimed |
| CN-113620901-A | Crown ether derived chiral 1,1 '-bi-2, 2' -naphthol, preparation method and application thereof | 杭州师范大学 | 2021-11-09 | — | — | CN | claimed |
| WO-1999052936-A2 | ARGININE PEPTIDE ANALOGS USEFUL AS FIBROBLAST GROWTH FACTOR ANTAGONISTS | EISAI CO., LTD. (JP) | 1999-10-21 | — | — | WO | claimed |
| CN-113620901-B | Crown ether derived chiral 1,1 '-bi-2, 2' -naphthol, preparation method and application thereof | 杭州师范大学 | 2023-02-10 | — | — | CN | disclosed |
| CN-113620901-A | Crown ether derived chiral 1,1 '-bi-2, 2' -naphthol, preparation method and application thereof | 杭州师范大学 | 2021-11-09 | — | — | CN | disclosed |
| EP-1783115-B1 | ARYLAMINE KETONES, THEIR PREPARATION METHODS, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | INST MATERIA MEDICA CAMS (CN) | 2016-07-13 | — | — | EP | disclosed |
| EP-2488501-B1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-04-30 | — | — | EP | disclosed |
| US-8524744-B2 | preventing and/or treating the diseases related to the plaque-activating factors, especially in anti-inflammation and immunization, more especially in the treatment of the acute or chronic inflammation, such as, osteoarthritis, oarthritis deformans, etc. | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-09-03 | — | — | US | disclosed |
| US-8357635-B2 | Microbiocides | SYNGENTA CROP PROTECTION LLC (US) | 2013-01-22 | — | — | US | disclosed |
| EP-2488501-A1 | NOVEL MICROBIOCIDES | Syngenta Participations AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-20120202867-A1 | NOVEL MICROBIOCIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-08-09 | — | — | US | disclosed |
| US-20080161288-A1 | COMPOUNDS | PFIZER INC. | 2008-07-03 | — | — | US | disclosed |
| CN-101146772-A | Arylamine ketone compound, synthesis method thereof, pharmaceutical composition containing arylamine ketone compound and application of arylamine ketone compound | INST MATERIA MEDICA CAMS (CN) | 2008-03-19 | — | — | CN | disclosed |
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | CHEMOCENTRYX, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| EP-1783115-A1 | ARYLAMINE KETONES, THEIR PREPARATION METHODS, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2007-05-09 | — | — | EP | disclosed |
| WO-1999052936-A2 | ARGININE PEPTIDE ANALOGS USEFUL AS FIBROBLAST GROWTH FACTOR ANTAGONISTS | EISAI CO., LTD. (JP) | 1999-10-21 | — | — | WO | disclosed |
| EP-0036718-B1 | 7-CHLORO-3-SUBSTITUTED ARYL-3,4-DIHYDRO-1,9(2H,10H) AND 10-HYDROXY ACRIDINEDIONEIMINES, PROCESSES FOR PRODUCING THE ACRIDINEDIONEIMINES, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE ACRIDINEDIONEIMINES | WARNER-LAMBERT COMPANY (US) | 1985-01-02 | — | — | EP | disclosed |
| EP-0036718-A2 | 7-Chloro-3-substituted aryl-3,4-dihydro-1,9(2H,10H) and 10-hydroxy acridinedioneimines, processes for producing the acridinedioneimines, and pharmaceutical compositions containing the acridinedioneimines | WARNER-LAMBERT COMPANY (US) | 1981-09-30 | — | — | EP | disclosed |
| US-4291034-A | 7-Chloro-3-substituted aryl-3,4-dihydro-1,9(2H,10H) and 10 hydroxy acridinedioneimines having antimalarial activity | WARNER LAMBERT COMPANY (US) | 1981-09-22 | — | — | US | disclosed |
| US-3989708-A | HYPOTENSIVE, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | C3AR1, C5AR1, C5AR2 | MAPT 4656/4885ALDH1A1 1488/4885KDM4E 4033/4885 |
| US-20080161288-A1 | COMPOUNDS | ADRB2, ADRB1, ADRA2C | MAPT 1735/4885ALDH1A1 295/4885KDM4E 4170/4885 |
| US-20120202867-A1 | NOVEL MICROBIOCIDES | CD14, FPR1, MPO | MAPT 4778/4885ALDH1A1 433/4885KDM4E 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.